The Association Between CYP2C19 Genotype and of In-stent Restenosis Among Patients with Vertebral Artery Stent Treatment.

CONCLUSION: The study leads to the conclusion that hyperlipidemia and CYP2C19 impotency are possible risk factors for the development of ISR in VAS-treated patients with ischemic. Moreover, VAS-treated patients with CYP2C19 impotency were susceptible to recurrent stroke during our 54-month follow-up.
PMID: 24330577 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - December 12, 2013 Category: Neuroscience Authors: Lin YJ, Li JW, Zhang MJ, Qian L, Yang WJ, Zhang CL, Shao Y, Zhang Y, Huang YJ, Xu Y Tags: CNS Neurosci Ther Source Type: research